Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

Journal of Hepatology

Volumn 55, Issue 1, 2011, Pages 76-85

  Grebely, Jason ^a   Matthews, Gail V ^a,b   Hellard, Margaret ^c,d   Shaw, David ^e   Van Beek, Ingrid ^f   Petoumenos, Kathy ^a   Alavi, Maryam ^a   Yeung, Barbara ^a   Haber, Paul S ^a   Lloyd, Andrew R ^g   Kaldor, John M ^a   Dore, Gregory J ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f Kirketon Road Centre ^*  (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Discontinuation; HIV infection; Injection drug users; Pegylated interferon; Therapy

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FATIGUE; FEMALE; HEPATITIS C; HUMAN; INSOMNIA; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MOOD DISORDER; MULTICENTER STUDY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958807454     PISSN: 01688278     EISSN: 01688278     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.10.033     Document Type: Article

References (38)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
4. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh, E. Lissen, J. Gonzalez-Garcia, and A. Lazzarin Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450 (Pubitemid 38988593)
5. R.T. Chung, J. Andersen, P. Volberding, G.K. Robbins, T. Liu, and K.E. Sherman Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459 (Pubitemid 38988594)
6. D.M. Jensen, T.R. Morgan, P. Marcellin, P.J. Pockros, K.R. Reddy, and S.J. Hadziyannis Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 2006 954 960 (Pubitemid 43724620)
7. A.U. Neumann, S. Pianko, S. Zeuzem, E.M. Yoshida, Y. Benhamou, and M. Mishan Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naive patients with genotype 1, chronic hepatitis C J Hepatol 51 2009 21 28
8. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
9. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, and M.L. Abate IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
10. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, and N. Sakamoto Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
11. J.G. McHutchison, M. Manns, K. Patel, T. Poynard, K.L. Lindsay, and C. Trepo Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
12. D.L. Sylvestre, and B.J. Clements Adherence to hepatitis C treatment in recovering heroin users maintained on methadone Eur J Gastroenterol Hepatol 19 2007 741 747 (Pubitemid 47266701)
13. V. Lo Re 3rd, V.K. Amorosa, A.R. Localio, R. O'Flynn, V. Teal, and Z. Dorey-Stein Adherence to hepatitis C virus therapy and early virologic outcomes Clin Infect Dis 48 2009 186 193
14. J.J. Weiss, N. Brau, A. Stivala, T. Swan, and D. Fishbein Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research Aliment Pharmacol Ther 30 2009 14 27
15. G. Calleri, G. Cariti, F. Gaiottino, F.G. De Rosa, O. Bargiacchi, and S. Audagnotto A short course of pegylated interferon-alpha in acute HCV hepatitis J Viral Hepat 14 2007 116 121 (Pubitemid 46146706)
16. B. Broers, B. Helbling, A. Francois, P. Schmid, C. Chuard, and A. Hadengue Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C J Hepatol 42 2005 323 328 (Pubitemid 40254245)
17. S.M. Kamal, A. Ismail, C.S. Graham, Q. He, J.W. Rasenack, and T. Peters Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics Hepatology 39 2004 1721 1731 (Pubitemid 38702674)
18. S.M. Kamal, K.N. Moustafa, J. Chen, J. Fehr, A. Abdel Moneim, and K.E. Khalifa Duration of peginterferon therapy in acute hepatitis C: a randomized trial Hepatology 43 2006 923 931 (Pubitemid 43724617)
19. S.M. Kamal, A.E. Fouly, R.R. Kamel, B. Hockenjos, A. Al Tawil, and K.E. Khalifa Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response Gastroenterology 130 2006 632 638 (Pubitemid 43374512)
20. T. Santantonio, M. Fasano, E. Sinisi, A. Guastadisegni, C. Casalino, and M. Mazzola Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance J Hepatol 42 2005 329 333 (Pubitemid 40254246)
21. J. Wiegand, P. Buggisch, W. Boecher, S. Zeuzem, C.M. Gelbmann, and T. Berg Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study Hepatology 43 2006 250 256
22. G.J. Dore, M. Hellard, G.V. Matthews, J. Grebely, P.S. Haber, and K. Petoumenos Effective treatment of injecting drug users with recently acquired hepatitis C virus infection Gastroenterology 138 2010 123 135 [e121-122]
23. M. Vogel, J. Nattermann, A. Baumgarten, G. Klausen, B. Bieniek, and K. Schewe Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals Antivir Ther 11 2006 1097 1101 (Pubitemid 44955186)
24. Y.C. Gilleece, R.E. Browne, D. Asboe, M. Atkins, S. Mandalia, and M. Bower Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin J Acquir Immune Defic Syndr 40 2005 41 46 (Pubitemid 41233203)
25. J. Grebely, S. deVlaming, F. Duncan, M. Viljoen, and B. Conway Current approaches to HCV infection in current and former injection drug users J Addict Dis 27 2008 25 35
26. M. Hellard, R. Sacks-Davis, and J. Gold Hepatitis C treatment for injection drug users: a review of the available evidence Clin Infect Dis 49 2009 561 573
27. S. Darke, W. Hall, A. Wodak, N. Heather, and J. Ward Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index Br J Addict 87 1992 733 742
28. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, and E. Weiller The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry 59 1998 22 33 [quiz 34-57] (Pubitemid 29001829)
29. J.D. Henry, and J.R. Crawford The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample Br J Clin Psychol 44 2005 227 239 (Pubitemid 40873436)
30. R. Sola, J.A. Galeras, S. Montoliu, C. Tural, L. Force, and S. Torra Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment AIDS Res Hum Retroviruses 22 2006 393 400 (Pubitemid 43787763)
31. C.R. Fumaz, J.A. Munoz-Moreno, A.L. Ballesteros, R. Paredes, M.J. Ferrer, and A. Salas Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients AIDS Care 19 2007 138 145 (Pubitemid 44852420)
32. S.R. Smith, A.S. Wahed, S.S. Kelley, H.S. Conjeevaram, P.R. Robuck, and M.W. Fried Assessing the validity of self-reported medication adherence in hepatitis C treatment Ann Pharmacother 41 2007 1116 1123 (Pubitemid 47122547)
33. J.J. Weiss, L. Bhatti, D.T. Dieterich, B.R. Edlin, D.A. Fishbein, and M.B. Goetz Hepatitis C patients' self-reported adherence to pegylated interferon and ribavirin Aliment Pharmacol Ther 28 2008 289 293
34. P. Cacoub, D. Ouzan, P. Melin, J.P. Lang, M. Rotily, and T. Fontanges Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study World J Gastroenterol 14 2008 6195 6203
35. T. Swan, and J. Curry Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users Hepatology 50 2009 323 324 [author reply 324-325]
36. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
37. M. Sherman, S. Shafran, K. Burak, K. Doucette, W. Wong, and N. Girgrah Management of chronic hepatitis C: consensus guidelines Can J Gastroenterol 21 2007 25C 34C (Pubitemid 47177083)
38. J. Grebely, J.D. Raffa, C. Meagher, F. Duncan, K.A. Genoway, and M. Khara Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users J Gastroenterol Hepatol 22 2007 1519 1525 (Pubitemid 47277379)